Ungated Post | 06 Mar 2020

Making cells better: Complex challenges drive innovation in cell and gene therapy manufacturing

The processes required for C&GT manufacture are wholly new and extremely complex. As production and delivery of these new therapies to patients are still nascent, biopharmaceutical companies will need to harness new technological advances and innovate continuously in the manufacturing process.

Large capital investments in the industry are likely to bring breakthroughs in the coming years that will standardise processes, simplify delivery logistics, boost efficiency, and increase competition.


Read the full report


Our Thought Leadership team produces original, evidence-based research made accessible to decision-makers and opinion leaders. Principals for this project included:

Oxford Economics’ team is expert at applying advanced economic tools that provide valuable insights into today’s most pressing business, financial, and policy issues.

To find out more about our capabilities, contact:

EMEA
Paul Donnelly
020 3910 8000
Email

Americas
Jeffrey Klonoski
+1 646 503 3048
Email

Asia
Christie Tang
+852 3974 8841
Email

Related Services

Post

The Relevance of Silver in a Global Multi-Asset Portfolio

This study examines whether silver should be viewed as a distinct asset class that warrants a strategic investment allocation within an efficient multi-asset portfolio.

Find Out More

Post

Achieving data-led innovation for the modern supply chain

A persistent pandemic, economic uncertainty, and a global geopolitical conflict continue to dominate headlines and fuel Chief Supply Chain Officer (CSCO) frustrations. Navigating uncertainties—and managing supply chain challenges accordingly—has out of necessity become a top business priority for boards and C-suites alike.

Find Out More

Post

The Economic Impact of Drax Group in the U.K., U.S. and Canada

This study investigates Drax Group’s economic impact in the U.K., U.S., and Canada. It considers Drax’s own operations, the economic activity supported by its procurement spending and the impact of the wage payments to employees. We also consider the social value delivered by Drax Group.

Find Out More